Drug Trial Radar · NCT06610071
NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique
Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
592
Planned (sponsor's estimate)
Start
Oct 30, 2024
Primary completion
Dec 2028
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking University Third Hospital; Chinese PLA General Hospital; Peking University International Hospital
- First posted
- Sep 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study will evaluate how near-infrared fluorescence (NIRF) imaging with low-dose second window indocyanine green (ICG) can assist in the radical resection and pathologic diagnosis of malignant soft tissue sarcoma, such as dermatofibrosarcoma protuberans (DFSP) and skin squamous cell carcinoma (sSCC) during surgery.
Conditions
- Dermatofibrosarcoma Protuberans (DFSP)
- Skin Squamous Cell Carcinoma
Interventions
ICG administrationDrug
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
ICG administrationDrug
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
ICG administrationDrug
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group
ICG administrationDrug
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 2-year local recurrence rateTime frame: up to 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.